Algeron (cepeginterferon alfa-2b) / Biocad  >>  Phase 3
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Algeron (cepeginterferon alfa-2b) / Biocad
NCT02103439: An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients

Completed
3
140
RoW
Algeron, Cepeginterferon alfa-2b, PegIntron, peginterferon alfa-2b
Biocad
Hepatitis, Hepatitis C, Hepatitis C/ Human Immunodeficiency Virus Coinfection
08/15
08/15
NCT01889433: An Open-label Comparative Efficacy and Safety Study of Algeron (Cepeginterferon Alfa-2b) in Treatment-naive Patients With Chronic Hepatitis C

Completed
3
170
RoW
Algeron, Cepeginterferon alfa-2b, Pegasys, Peginterferon alfa-2a
Biocad
Hepatitis, Hepatitis C
12/15
12/15
NCT01740089: Algeron (Cepeginterferon Alfa-2b) Compared With PegIntron (Peginterferon Alfa-2b) for Treatment of Chronic Hepatitis C

Completed
2/3
150
RoW
Algeron, cepeginterferon alfa-2b, PegIntron, Peginterferon alfa-2b, Ribavirin
Biocad
Hepatitis, Hepatitis C
07/12
12/13

Download Options